Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk (NVO) stock has seen significant underperformance, down over 61% in the past year, after the company slashed its full-year guidance, revising sales growth expectations to 8-14% from 13-21% and operating profit to 10-16% from 16-24%. This downgrade is attributed to intense competition from cheaper compounded GLP-1 drugs, lower-than-expected international market penetration, and rivalry with Eli Lilly. With a new CEO taking the helm and the stock trading at a discount to historical averages, investors are keenly awaiting the August 6 earnings report for clarity on whether the recent sell-off is overdone amidst these competitive pressures.

Analysis

Novo Nordisk (NVO) is facing significant investor pressure following a substantial stock decline of over 61% in the last year, exacerbated by a recent guidance cut that triggered a 3% drop in one week. The company lowered its full-year sales growth forecast to a range of 8-14% from a previous 13-21%, and its operating profit growth outlook to 10-16% from 16-24%. This revision is attributed to multiple headwinds, including intense competition from cheaper compounded GLP-1 drugs, which can be 50-70% less expensive, and market share gains by rival Eli Lilly & Co. (LLY). Further complicating the outlook is lower-than-expected penetration in international markets and inconsistent insurance coverage for its obesity drug, Wegovy, which fuels demand for the compounded alternatives. Despite these challenges, the stock's valuation has become more attractive, trading at approximately 12x forward earnings, a discount to both its historical average and the sector. The company remains profitable with year-over-year growth, and technical indicators such as a low RSI suggest the stock may be in oversold territory. The upcoming earnings report on August 6, which coincides with the start date for new CEO Maziar Mike Doustdar, is a critical catalyst that will provide clarity on whether the recent, sharp sell-off is justified.

Key Decisions for Investors

• Given the stock is trading at a discount to its historical averages and technical indicators suggest it is oversold, investors with a high risk tolerance could consider the current price a potential entry point ahead of the August 6 earnings report.
• Investors should closely scrutinize the upcoming earnings call for management's updated strategy on combating compounded drug competition and addressing weaker-than-expected international penetration, as these are the primary drivers of the revised guidance.
• It is prudent to monitor the competitive dynamics, specifically any further market share gains by Eli Lilly and the efficacy of Novo Nordisk's legal actions against compounded drug producers, as these factors will heavily influence the company's long-term profitability.